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Abstract 
We have previously reported the whole genome genotyping analysis of two 
consanguineous siblings clinically diagnosed with early onset Alzheimer’s disease. In 
this analysis we identified several large regions of homozygosity shared between 
both affected siblings, which we suggested could be candidate loci for a recessive 
genetic lesion underlying the early onset Alzheimer’s disease in these cases. We 
have now performed exome sequencing in one of these siblings and identified the 
potential cause of disease: the CTSF c.G1243A:p.Gly415Arg mutation in 
homozygosity. Bi-allelic mutations in this gene have been shown to cause Type B 
Kufs disease, an adult-onset neuronal ceroid lipofuscinosis with some cases 
resembling the impairment seen in Alzheimer’s disease. 
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1. Introduction 
The absence of consanguineous families in the deeply characterized datasets of 
North America and Europe has made mapping of recessive loci challenging in 
Alzheimer’s disease (AD) (Ghani, et al., 2015). Nonetheless, a recent study 
suggested that nearly 90% of early-onset AD (EOAD) cases are likely the result of 
autosomal recessive inheritance (Wingo, et al., 2012). In 2009 we described the 
whole genome genotyping analysis of two EOAD siblings from a Jewish Israeli family 
originating from Morocco whose parents were first cousins and neurologically healthy 
(Clarimon, et al., 2009). At that time the formal assessment of a recessive aetiology 
in EOAD cases had not been systematically performed and the identification of large 
tracts of homozygosity shared between these two affected siblings added information 
to the possibility of recessive heritability being part of this disease. Currently, two 
mutations in APP are known to cause AD through an autosomal recessive pattern of 
inheritance. The p.Ala673Val has been found to cause disease only in the 
homozygous state, whereas heterozygous carriers were found to be unaffected. This 
mutation was also shown to affect APP processing with co-incubation of mutated and 
wild-type peptides conferring instability on Aβ aggregates and inhibiting 
amyloidogenesis and neurotoxicity. The highly amyloidogenic effect of the 
p.Ala673Val mutation in the homozygous state and its anti-amyloidogenic effect in 
the heterozygous state accounted for the autosomal recessive pattern of inheritance 
of the disease (Di Fede, et al., 2009). Similarly, the p.Glu693Δ was found to 
segregate in a Japanese family with an autosomal recessive pattern. In this case the 
secretion of total Aβ was markedly reduced by the mutation, but the variant Aβ was 
more resistant to proteolytic degradation (Tomiyama, et al., 2008).  
The contribution of long runs of homozygosity (ROHs) to AD has also been tested in 
different populations with diverse results. The global burden of large genome-wide 
ROHs in outbred datasets from North America and Europe did not show a significant 
association with AD (Nalls, et al., 2009,Sims, et al., 2011). In the Wadi Ara 
population (an isolated Arab community from northern Israel) the controls studied 
were found to have more ROHs than the AD cases (Sherva, et al., 2011) and ROHs 
were found to be significantly associated with AD in a Caribbean Hispanic data set 
(Ghani, et al., 2013) and in an outbred African American population (Ghani, et al., 
2015). 
In this study we used exome sequencing in order to identify any potential pathogenic 
mutations within long ROHs shared between two siblings from a consanguineous 
family, clinically diagnosed with EOAD. 
2. Methods 
2.1. Patients 
We analyzed a previously described Jewish Israeli family originating from Morocco 
(Clarimon, et al., 2009). The family was composed of seven siblings born to first-
degree consanguineous parents who died after the age of 90 years without any signs 
of cognitive impairment. Two siblings were diagnosed with EOAD and agreed to 
participate in the genetic study. The others refused to give samples for genetic 
analyses. Written informed consent was obtained from both patients included in the 
study.  
2.2. Genetic analyses 
In our previous study we sequenced PSEN1 (exons 3–12), PSEN2 (exons 3–12), 
APP (exons 16 and 17), TAU, PGRN, and PRNP and found no pathogenic mutations 
in these genes. We moved on to perform whole genome genotyping using an 
Illumina Human-Hap240S genotyping array in the two siblings to identify long ROHs 
(>1MB) shared between them (Clarimon, et al., 2009). Now we have performed 
exome sequencing in one of the siblings. For this analysis we prepared genomic 
DNA according to Illumina’s TruSeq Sample Preparation v.3 and performed the 
exome capture with Illumina’s TruSeq Exome Enrichment according to the 
manufacturer’s instructions. Sequencing was performed on an Illumina HiSeq2500 
with 100-bp paired-end reads. Following quality control procedures, the sample 
yielded 10.2 Gb of high-quality, aligned data. This amount of data resulted in a mean 
target coverage of 35.8x, 83% of targets being covered at greater than or equal to 
10×, and less than 0.2% of targets not being covered at least once. We performed 
sequence alignment and variant calling against the reference human genome (hg19) 
by using the Burrows-Wheeler Aligner (Li and Durbin, 2009) and the Genome 
Analysis Toolkit (DePristo, et al., 2011,McKenna, et al., 2010). Prior to variant calling, 
PCR duplicates were removed with the Picard software. On the basis of the 
hypothesis that the mutation was rare, we excluded all common variants (MAF > 5%) 
identified in dbSNP v.142 and in our in-house database of sequencing data for other 
diseases (n > 2,000). Given the apparent autosomal-recessive mode of inheritance in 
the family and the previous whole genome genotyping data, we focused the analysis 
on homozygous variants located in the shared ROHs. The vast majority of known 
coding exons within these ROHs (93%) were adequately covered (5x or more). We 
used Sanger sequencing to confirm the variant of interest identified by exome 
sequencing and to establish the presence of the variant in the second sibling. 
Because of the low amount of DNA available for analyses we performed whole 
genome amplification of both samples using the REPLI-g Amplification kit (Qiagen) 
before confirming the additional 10 variants identified by exome sequencing in the 
shared ROHs. For all variants we performed PCR amplification and purified the 
resulting products with ExoSAP-IT (USB), then performed direct Sanger sequencing 
of both strands using BigDye Terminator v.3.1 chemistry v.3.1 (Applied Biosystems) 
and an ABI 3730XL Genetic Analyzer (Applied Biosystems). Sequencing traces were 
analyzed with Sequencher software v.4.2 (Gene Codes). 
3. Results 
3.1. Family description 
As previously described, the family consisted of seven siblings from a first-cousin 
marriage (Clarimon, et al., 2009). At the time of the clinical study the mother was 90 
years old with mild gait difficulties but otherwise healthy, with no cognitive loss. The 
father died at age 90 due to cerebral stroke. The proband is a 64-year-old man who 
was born in Morocco and migrated to Israel in 1956. At the age of 58 he presented 
with a 9-month history of insidious, progressive impairment of memory first noticed 
by the family. Early symptoms were repeated questioning, forgetting names and loss 
of interest in his family. Two months after the initial visit, the Mini-Mental State 
Examination score was 9/30. Cognitive examination revealed diffuse cognitive 
impairment, most notably of short and long-term memory, verbal and visual recall, 
and visuospatial abilities. Calculation, attention tasks, and information processing 
speed were markedly impaired. In addition, he had moderate dressing apraxia and 
right–left disorientation. According to the NINCDS-ADRDA criteria the clinical 
examination and neuropsychological profile were consistent with EOAD (McKhann, 
et al., 1984). One of his siblings initially presented clinical symptoms at the age of 58, 
when he was laid-off from work due to cognitive decline. One year later, he was 
institutionalized in a psychiatric institution with a clinical diagnosis of EOAD. He died 
at the age of 70 and did not present any extrapyramidal signs during the course of 
disease. The diagnoses were established based on the clinical presentation of the 
siblings and it was not possible to establish biomarker or neuropathological 
confirmation of these diagnoses. 
3.2. Exome and Sanger sequencing analyses 
We identified 8312 variants in the exome sequenced sample with a high or medium 
effect in the gene (nonsynonymous missense, nonsense, affecting splicing sites, 
nonframeshift and frameshift insertions/deletions). From these, 3921 were 
homozygous. Based on the hypothesis that the mutation underlying the disease in 
this family is rare, we filtered the results to include variants with minor allele 
frequencies (MAFs) <0.001 in the 1000 Genomes Project and the ExAC datasets, 
resulting in 39 variants (12 indels, 26 nonsynonymous and 1 splicing variants), 14 of 
which were novel. From these, 11 variants were located in genes within the shared 
ROHs (Table 1). The bioinformatics analysis of these 11 variants involved the 
determination of genomic conservation for the variant locus; prediction of the effect in 
the protein using different predictive algorithms; information regarding the expression 
of the respective gene in brain tissue; and a constraint metric evaluating the 
probability of the gene being intolerant to variation. Details for this analysis are 
presented in Supplementary Table 1. Only one variant was found to follow all the 
inclusion and exclusion criteria: Cathepsin F (CTSF) p.[(Gly415Arg)];[(Gly415Arg)] 
(NM_003793; c.[1243G>A];[1243G>A]). Sanger sequencing confirmed the presence 
of the variant in both siblings. This variant is present in 10 of 74678 alleles in the 
ExAC dataset (MAF=0.0001) and is never seen in homozygosity. In fact, no CTSF 
loss of function variants are present in homozygosity in this dataset (Exome 
Aggregation Consortium [ExAC], Cambridge, MA (URL: 
http://exac.broadinstitute.org), accessed August 2015). The mutation is predicted to 
be damaging/deleterious/disease causing by Polyphen-2, SIFT and MutationTaster, 
respectively and is highly conserved both between species and between the human 
members of the papain family of cysteine proteases (Figure 1).  
Because of the low amounts of DNA available for analyses, whole genome 
amplification of both samples was done before PCR and Sanger sequencing to 
confirm the additional 10 variants. Seven of these variants were confirmed before 
complete exhaustion of the DNA (Supplementary Table 1). 
Table 1. Variants identified by exome sequencing that map to previously determined 
regions of homozygosity shared between both affected siblings. 
ROH Variants from exome sequencing 
Chr Start End Gene NM_reference Variant 
Chr 1 
64,831,392 76,777,065    
120,351,977 146,978,395    
222,206,887 223,349,930       
Chr 2 
99,769 7,554,772    
194,236,059 195,771,061       
Chr 3 
16,507,325 19,786,794 TBC1D5 NM_014744 c.C509T:p.T170M 
61,615,203 71,702,005    
80,535,924 81,815,563    
101,669,900 115,238,487 ATG3 NM_001278712 c.920dupT:p.L307fs 
Chr 4 109,954,423 129,247,395 QRFPR NM_198179 c.A770G:p.H257R 
Chr 5 
34,551,865 55,308,631 OXCT1 NM_000436 c.T91G:p.S31A 
67,406,227 90,609,868       
Chr 6 11,274,139 20,983,442       
Chr 8 
33,181,258 34,327,790    
131,984,210 135,151,005       
Chr 9 46,587 3,844,391       
Chr10 
73,459,856 79,225,270 DUSP13 NM_001007272 c.G337C:p.D113H 
106,135,117 112,191,992       
Chr11 
19,083,477 78,642,077 OR5F1 NM_003697 c.C398T:p.S133F 
  TNKS1BP1 NM_033396 c.G600T:p.R200S 
  CTSF NM_003793 c.G1243A:p.G415R 
    NUMA1 NM_001286561 c.A6128G:p.K2043R 
Chr13 
60,847,162 62,345,896    
85,729,553 95,634,313       
Chr14 74,702,249 75,774,346       
Chr16 66,947,783 68,839,302    
Chr17 37,386,899 43,423,890 MLX FZD2 
NM_170607 
NM_001466 
c.G263A:p.R88H 
c.G757C:p.V253L 
Chr: chromosome; Start-End: Chromosome positions (hg 19) of the beginning and 
end of all long regions of homozygosity (>1Mb) shared between both affected 
siblings.  
The subsequent analysis of our in-house exome sequencing data for Alzheimer’s 
disease cases (542 EOADs and 185 late onset ADs) revealed a second variant of 
potential interest in an EOAD case. This homozygous mutation c.214-6C>T was 
present in the splice site region of CTSF exon 2. The same variant is present in 
homozygosity in one sample and in heterozygosity in 46 samples of the ExAC 
database. The mutation was found in a proband originally from Slovakia presenting 
with a history of dementia and possible myoclonus. The patient was 46 years old at 
the time of clinical onset, and 51 at time of sampling. There were white matter 
changes in subcortical regions on MRI. No family history of dementia and no other 
samples from family members were available for analysis, however the presence of 
this variant in homozygosity in the ExAC database argues against its pathogenicity in 
EOAD. 
The CTSF locus on chromosome 11 has not been identified as associated with 
Alzheimer’s disease by any of the reports analyzing long runs of homozygosity 
(Supplementary Table 2).  
4. Discussion 
The availability of only two samples from this family for genetic analyses precludes 
the definitive conclusion about the genetic cause of recessive dementia in the two 
siblings studied. However, the results obtained from exome sequencing the proband 
indicate the possible involvement of CTSF in the phenotype. The brothers are likely 
to be AD phenocopies with Kufs’ pathology, but the unavailability of samples for 
pathology analyses do not allow us to confirm this hypothesis.  
Bi-allelic mutations in CTSF have been previously identified as the cause of type B 
Kufs disease (Smith, et al., 2013). This is the most common adult form of neuronal 
ceroid lipfuscinosis (NCLs), which are neurodegenerative diseases mainly 
characterized by the abnormal accumulation of lipopigment in lysosomes. The 
diagnosis of Kufs disease is often very challenging and the definitive diagnosis may 
require the neuropathological assessment of brain tissue (Smith, et al., 
2013,Williams and Mole, 2012). 
Kufs disease is genetically heterogeneous with mutations in CLN6 known to cause 
recessive Type A disease and mutations in DNAJC5 underlying some cases of 
dominant Kufs (Arsov, et al., 2011,Benitez, et al., 2011,Noskova, et al., 2011). Type 
A is characterized by progressive myoclonus epilepsy and cognitive decline; and 
type B is characterized by movement and behavioral abnormalities associated with 
dementia (Berkovic, et al., 1988). More recently, mutations in CTSF have been 
identified as the cause of recessive type B Kufs disease, characterized by dementia 
and motor features (Di Fabio, et al., 2014,Smith, et al., 2013). 
Four homozygous or compound heterozygous CTSF mutations have been 
associated with Kufs disease: p.[(Gly458Ala)];[(Ser480Leu)], 
p.[(Gln321Arg)];[(Gln321Arg)], p.[(Tyr231Cys)];[(Ser319Leufs∗27)], and 
c.[213+1G>C];[213+1G>C]. Most of these are located in the peptidase C1 domain 
towards the C-terminal end of CTSF and are predicted to affect the protein function 
(Figure 2). The fourth mutation (c.[213+1G>C];[ 213+1G>C]) has been shown to 
create an mRNA lacking exon 1 and was predicted to form a truncated N-terminus of 
cathepsin F 20% shorter than the wild-type protein with a possible loss-of-function 
acting in a pseudo-dominant fashion (Di Fabio, et al., 2014). 
Of the 9 reported cases from 4 families, 8 were women. The onset of the disease 
occurred on average at 32.7+/-15.3 years with seizures. Progressive cognitive 
impairment was present in all cases at an average age of 40+/-14.2 years (Table 2) 
(Di Fabio, et al., 2014,Smith, et al., 2013). 
Table 2. Main features of patients reported within families with CTSF mutations.  
 Smith et al. Ku4 Smith et al. Ku10 Smith et al. Ku16 Di Fabio et al. 
 Proband Older sister Proband Proband Proband IV-3 Mother III-4 
Maternal aunt 
III-5 Cousin V-1 
Cousin 
IV-1 
Origin Italy France-Canada Australia Italy (Fondi) 
Consanguinity No Yes No Yes 
Gender Female Female Female Female Female Female Female Female Male 
AAE/AAD AAD 42 AAE ~54 AAE 53 AAE 40 AAE 42 AAD 56 AAE 74 AAE 45 AAD 67 
AAO 20 32 24 35 23 25 66 21 48 
First 
manifestation Tremor Depression Focal seizures Cognitive decline 
Tonic-clonic 
seizures 
Tonic-clonic 
seizures 
Tonic-clonic 
seizures (after 
head trauma) 
Tonic-clonic 
seizures 
Tonic-
clonic 
seizures 
Seizures Rare (from 28) Rare (from 41) Yes Rare (from 39) 23 25 66 21 48 
Cognitive 
impairment 30 32 35 35 30 35 69 
39 (after 
head 
trauma) 
55 
Other features 
Ataxia and 
dysarthria; no 
myoclonus; no 
epileptiform activity 
From age 42, 
ataxia and 
dysarthria were 
noted and 
subsequently 
pyramidal and 
extra-pyramidal 
motor features 
were seen; no 
epileptiform 
activity 
From age 35 she 
had progressive 
dementia with 
mood disturb- 
ance and motor 
features including 
tremor, ataxia, 
and extra- 
pyramidal type 
rigidity with mild 
hypereflexia. 
Mild cerebellar 
dysarthria and mild 
gait ataxia with 
tremor and past-
pointing 
Cerebellar 
dysarthria; 
transient 
perioral 
dyskinesias 
and segmental 
myoclonic 
jerks 
Behavioral 
disturbances
, emotional 
lability and 
intellectual 
deterioration 
Confined to a 
wheelchair, 
aphasic and  
with severe 
dementia. 
Postural 
tremor in the 
upper limbs; 
action 
myoclonus 
and perioral 
dyskinesias 
Rapidly 
progressive 
cognitive 
decline after 
head 
trauma; 
cerebellar 
dysarthria, 
occasional 
dysphasia 
with 
confabulatio
n, ideomotor 
apraxia, 
inappropriate 
laughing, 
and urinary 
incontinence 
Severe 
dementia 
Mutation p.[(Gly458Ala)];[(Ser480Leu)] 
p.[(Gly458Ala)];[(S
er480Leu)] 
p.[(Gln321Arg)];[(
Gln321Arg)] 
p.[(Tyr231Cys)];[(Se
r319Leufs∗27)] 
c.[213+1G>C];
[213+1G>C] NA 
c.[213+1G>C];
[213+1G>C] 
c.[213+1G>
C];[213+1G>
C] 
NA 
AAE/AAD: Age at examination/Age at death; AAO: age at onset; NA: not available 
 
 
 
All identified mutations were associated with a clinical picture of Kufs disease 
characterized by an older age at onset, seizures and delayed cognitive decline. 
However, even within the same kindred, significant differences were observed in the 
clinical presentation of the disease, which seem to happen within a spectrum 
between typical Kufs disease and late onset cognitive impairment (Di Fabio, et al., 
2014,Smith, et al., 2013). 
Even though no seizures were reported in the two siblings studied here, and they 
had a typical clinical presentation of Alzheimer’s disease with the first signs of 
dementia at 58 years, given the broad presentation of CTSF mutations and the 
challenging diagnosis of Kufs B disease, CTSF p.[(Gly415Arg)];[(Gly415Arg)] is the 
most probable genetic cause of disease. The difficulty in the diagnosis of Kufs 
disease and the overlap with Alzheimer’s disease has been recently highlighted by 
the finding of a novel PSEN1 mutation (p.Leu381Phe) in a family originally diagnosed 
with Kufs disease. Electron microscopy studies of the proband’s skin biopsy showed 
lipofuscin containing phagocytic cells and distinct curvilinear lysosomal inclusion 
bodies, which were highly suggestive of NCL (Dolzhanskaya, et al., 2014). These 
results substantiate the suggestion that CTSF should be screened in cases of early-
onset recessive dementia. 
 
Figures captions 
Figure 1. Conservation alignment for the CTSF p.Gly415Arg variant. 
The CTSF residue found to be mutated is highly conserved throughout evolution, as 
shown by alignment of the protein sequences of CTSF orthologues in various 
organisms (A), as well as in the known human members of the papain family of 
cysteine proteases (B). Protein alignments were performed using the Clustal Omega 
software. In both panels (A and B) the symbols under the aminoacid sequences 
represent: “*” (asterisks) indicate positions which have a single, fully conserved 
residue; “:” (colons) indicate conservation between groups of strongly similar 
properties - scoring > 0.5 in the Gonnet PAM 250 matrix; and “.” (periods) indicate 
conservation between groups of weakly similar properties - scoring =< 0.5 in the 
Gonnet PAM 250 matrix. Gaps between the different protein sequences are 
represented by “-“ (dashes) within the sequences. In panel A only residues 376 to 
428 are represented, from a total of 484 amino acids in the human protein and 
corresponding region in the other organisms. In panel B only residues 410 to 446 are 
represented for Cathepsin F and corresponding region in the other members of the 
papain family of cysteine proteases. The boxes and underneath arrows indicate the 
residue found to be mutated in the siblings studied here (G415). 
Figure 2. Protein representation with the location of the CTSF mutations 
reported to be associated with Kufs disease. 
CTSF is represented with the depicted regions as predicted by Pfam (UniProt 
Q9UBX1) (Finn, et al., 2014). The variant identified in this study is represented in 
red. Most mutations are located in the peptidase C1 domain towards the C-terminal 
end of the protein and are predicted to affect the protein function.  
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